Participants
| Role | Name | HCID | Charge |
|---|
| Reactant | Sodium Carbonate | HCID 10340 | — |
| Reactant | HCID 20516774 | HCID 20516774 | — |
| Reactant | HCID 20516775 | HCID 20516775 | — |
| Reactant | HCID 20516784 | HCID 20516784 | — |
| Solvent | 1,2-Dichloroethane | HCID 11 | — |
| Solvent | Dichloromethane | HCID 6344 | — |
| Solvent | 1-(2-Hydroxyethyl)piperazine | HCID 7677 | — |
| Product | HCID 20516778 | HCID 20516778 | — |
Reaction Steps
A 1,2-dichloroethane solution of [6,8-dichloro-5-(o-fluorophenyl)-2,3-dihydro-1-methyl-2-oxo-1H-1,4-benzodiazepin-7-yl]isocyanate, prepared in analogy to the procedure described in paragraph (a) of Example 4 from 6 g (17.1 mmol) of 7-amino-6,8-dichloro-5-(o-fluorophenyl)-1,3-dihydro-1-methyl-2H-1,4-benzodiazepin-2-one, is treated with a suspension of 6.11 g of sodium carbonate in 6.3 ml of N-(2-hydroxyethyl)piperazine and 40 ml of methylene chloride. The mixture is stirred at room temperature for 138 hours and concentrated in vacuo. The residue is taken up in 1.5 liter of methylene chloride/ethanol (4:1), the solution is washed with 300 ml of water, dried over magnesium sulphate and evaporated. The residue is chromatographed on 250 g of silica gel using chloroform for the elution, there being obtained N-[6,8-dichloro-5-(o-fluorophenyl)-2,3-dihydro-1-methyl-2-oxo-1H-1,4-benzodiazepin-7-yl]-4-(2-hydroxyethyl)-1-piperazinecarboxamide. After recrystallisation from methylene chloride/hexane, the product melts at 232°-233° C.
Provenance & Evidence
| DOI | 10.6084/m9.figshare.5104873.v1 |
|---|
| Patent number | US04361511 |
|---|
| Source dataset | uspto-grants-1982_11 |
|---|
| ORD ID | ord-572fdcf0e14746419d6fd2fbf3af4b92 |
|---|
| Source note | uspto-grants-1982_11 |
|---|